Antisense treatment for psoriasis

Treatment Options for Pediatric Psoriasis.

Psoriasis is a multifactorial inflammatory papulosquamous disease affecting 0.5% to 2% of the pediatric population. Pediatric psoriasis, presenting similar to adult psoriasis, significantly reduces patient quality of life, often requiring an individualized treatment approach for each patient. Combination and rotational therapy are helpful in reducing toxicity and maximizing efficacy. Patients w...

Antisense oligonucleotides for the treatment of dyslipidemia.

New studies further demonstrate that lowering low-density lipoprotein (LDL)-cholesterol, at least with the use of statins, decreases the risk of cardiovascular disease (CVD). Subsequently national and international guidelines have set target levels for LDL-cholesterol that are progressively lower, making the likelihood of patients attaining them progressively more limited, even with the use of ...

Advances in Psoriasis Treatment

The treatment of psoriasis is changing, thanks to a growing understanding that it is a disease of systemic inflammation.1,2 In this regard, drug candidates targeting the interleukin-23 (IL-23) and type-17 helper (IL-23/Th17) T-cell pathway appear particularly promising, offering high rates of clearance or near-clearance of psoriatic lesions.3–5 Along with their role in treating psoriasis, ustek...

Treatment of Psoriasis

Emerging Therapies for the Treatment of Psoriasis

Psoriasis is an immune-mediated disease that affects 1%-2% of the European and North American population. While topical agents such as corticosteroids and vitamin D derivatives are prescribed for mild disease, they are generally unable to adequately control patients with more severe disease. Over the past decade, research into the immunopathogenesis of psoriasis, including investigations into t...